Resyca shareholder Bespak announces successful completion of spin-out from Recipharm Group
Separation creates leading global CDMO focused on inhaled and nasal drug delivery
Enschede, Netherlands and Holmes Chapel, UK; Tuesday 2nd April 2024 — Bespak, backed by EQT Private Equity, today announced the finalisation of its separation from the Recipharm Group to form a new standalone entity. Formerly the Advanced Delivery Systems Business Unit of Recipharm, the spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.
The announcement means that Resyca is now under the governance of Bespak alongside Medspray as the two shareholders. Resyca was founded in 2020 as a joint venture between Recipharm and Medspray, with governance under the Advanced Delivery Systems Business Unit of Recipharm. Following the separation, Resyca now operates under the umbrella of the newly established Bespak. Resyca will continue to be led by the Managing Directors, Remko Beimers (CEO) and Bernhard Müllinger (COO), and will continue its strategic direction under the existing Supervisory Board control, now comprising Han van Egmond (CEO, Medspray) and Chris Hirst (CEO, Bespak).
Remko Beimers, CEO, Resyca commented: “We at Resyca congratulate our colleagues at Bespak on the completion of a successful spin-out. We look forward to continuing to work closely with the team at Bespak to provide all aspects of an end-to-end solution for both oral and nasal inhalation, leveraging Medspray’s proprietary soft mist technology to create value for our customers.”
Han van Egmond, CEO at Medspray said: “We are delighted to be continuing to work with the experienced and familiar team, formerly Recipharm Advanced Delivery Systems, as they transition to their newly formed company, Bespak. Combining our cutting-edge soft mist technology with Resyca’s product development capabilities and Bespak’s industrialisation track record will redefine the landscape of pulmonary and nasal drug delivery.”
Chris Hirst, formerly President of the Advanced Delivery Systems Business Unit at Recipharm, has been named CEO of the newly formed Bespak. “The spin-out of three former Recipharm sites, each with a long history in inhaled and nasal drug delivery, creates a new company with a clear vision and a unique offering for customers. The new Bespak will be the trusted innovation partner and sustainability leader in the transition to greener inhalers. As a CDMO committed to driving innovation, we look forward to continuing to support Resyca in bringing pioneering soft mist devices to the market to improve patient experience and expand what is possible via the pulmonary and nasal delivery routes.”
About Bespak®
Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products. Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry. With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators, and also specialises in the industrialisation and high-volume manufacture of complex dry powder inhaler (DPI) devices.
Headquartered in Holmes Chapel, UK, the company’s service offering spans early-stage feasibility, analytical services and product development, from pilot-scale, through to clinical supply and commercial-scale drug product fill-finish, device and component manufacturing.
More information: www.bespak.com
About Medspray BV
Medspray is a privately owned company in Enschede, the Netherlands. With its 40 employees, Medspray focuses on the development and manufacturing of micro spray nozzles which are able to deliver soft mists. Medspray’s slogan is: “tiny technology for a sustainable future.” Medspray aims to contribute to a sustainable world by developing innovative spray nozzles for user-friendly health and physical care products – by making propellants redundant and increasing the user-friendliness for various purposes, especially where a slow-moving soft spray is required. Thanks to the high-tech nozzle chips, sprays can be tailored to suit any application, from inhalable aerosol clouds, to gentle nasal sprays, to cosmetic or fragrance sprays that do not feel wet on the skin.
More information: www.medspray.com
About Resyca®
Resyca® was founded in 2020 and is a joint venture between Bespak and Medspray. Resyca® specialises in the development and manufacturing of compact, user-friendly soft mist inhalation and soft nasal spray devices, incorporating the proprietary Medspray micro-nozzle technology. These devices are tailored for pulmonary and nasal applications, utilising standard pre-filled syringes / primary packaging and filling lines. As the soft mist development centre within Bespak, Resyca offers comprehensive services spanning from early-stage development through to commercial production, inclusive of filling, labelling, and packaging.
For further information and interview opportunities with Resyca®, please contact:
Bernhard Müllinger at Resyca BV
Email: info@resyca.com
Website: www.resyca.com
